Review Article
Lysine Acetylation: Elucidating the Components of an Emerging Global Signaling Pathway in Trypanosomes
Table 4
KDACs and KATs inhibitors tested in protozoan parasites.
| | Structure | Target | Antiparasitic activity |
| KDAC inhibitors | | | | Apicidin | Cyclic tetrapeptide | All KDAC | Apicomplexa T. gondii, P. falciparum | Apicidin analogues | Cyclic tetrapeptide with indole modifications | All KDAC | T. gondii, P. falciparum, T. brucei | Valproic acid | Short-chain fatty acid | Class I KDAC | P. falciparum, T. gondii | Sodium butyrate | Short-chain fatty acid | All KDAC | P. falciparum, T. gondii | Sirtinol | 2-hydroxy-1-napthaldehyde derivative | SIR2 | L. infantum amastigotes, P. falciparum, T. gondii | Nicotinamide | Noncompetitive inhibitor | SIR2 | Leishmania spp., T. cruzi epimastigotes | Tricostain A (TSA) | Natural hydroxamate based | Class I and II KDAC | T. cruzi, P. falciparum | Suberoylanilide hydroxamic acid (SAHA) | Synthetic hydroxamate based | All KDAC | P. falciparum | Hydroxamic acid derivatives | | All KDAC | T. brucei |
| KAT inhibitors | | | | Curcumin | Natural phenol | MYST family p300/CBP | T. brucei, L. mexicana | Garcinol | Polyisoprenylated benzophenone | MYST family p300 and PCAF | Leishmania spp. | Anarcadic acid | Salicylic acidsubstituted with analkylchain | MYST family p300 and PCAF, Tip60 | P. falciparum |
|
|